Eurofins to Offer GE's Cardiomyocytes in Toxicity Screening Services | GenomeWeb

NEW YORK (GenomeWeb News) — Eurofins said today that its Panlabs pharmacology services arm has signed an agreement with GE Healthcare giving it the exclusive right to offer GE's Cytiva cardiomyocytes for cardiotoxicity screening services.

Cardiomyocytes offer a cost-effective and time-efficient alternative to animal models for predictive cardiotoxicity testing in drug discovery and development, Eurofins said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.